Hologic reported a strong fiscal fourth quarter in 2024, with a 4.5% increase in revenue to $987.9 million. GAAP diluted EPS was $0.76, and non-GAAP diluted EPS was $1.01. The company expects strong execution of its broad-based growth strategy in fiscal 2025.
Revenue increased by 4.5% to $987.9 million.
Diagnostics revenue increased 6.5%, driven by higher Molecular Diagnostics sales.
Breast Health revenue increased 6.4%, driven by strong Breast Imaging Service revenue and the addition of Endomagnetics.
The Company intends to enter into an accelerated share repurchase (ASR) agreement for $250 million of the Company’s common stock.
Hologic provided financial guidance for the first quarter and full year 2025, incorporating the expected impact from the ongoing temporary stop-ship of Horizon DXA systems (Skeletal).
Visualization of income flow from segment revenue to net income